News & Press.
Learn the Latest Elutia Updates
Elutia Awarded Cardiac Rhythm Management Devices Agreement with Premier, Inc.
SILVER SPRING, Md., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, announced it has been awarded a national group purchasing agreement for Cardiac Rhythm...
Elutia Announces Strong Third Quarter Results, Accelerating Toward Full Launch of EluPro® Antibiotic-Eluting BioEnvelope in 2025
Over 100 EluPro VAC Submissions and 19% SimpliDerm Growth Drive Momentum into 2025 SILVER SPRING, Md., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, today...
Elutia to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
SILVER SPRING, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a leader in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, Matt Ferguson,...
Elutia to Report Third Quarter 2024 Financial Results on Thursday, November 14, 2024
SILVER SPRING, Md., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a leader in drug-eluting biomatrix products, today announced that it will release its third quarter 2024 financial results after market...
Elutia to Present at the LD Micro Main Event XVII Conference on Wednesday, October 30
SILVER SPRING, Md., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a leader in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, will present at the LD Micro Main...